IAS-LAB PUBLICATIONS
25/03/2026 04:22:47
Authors: 2429 STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA; 2-s2.0-85047747972 29861076
Journal: Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial
Published: 16590
DOI: 10138
eng
Volume: Caraceni P.; Riggio O.; Angeli P.; Alessandria C.; Neri S.; Foschi F.G.; Levantesi F.; Airoldi A.; Boccia S.; Svegliati-Baroni G.; Fagiuoli S.; Romanelli R.G.; Cozzolongo R.; Di Marco V.; Sangiovanni V.; Morisco F.; Toniutto P.; Tortora A.; De Marco R.; Angelico M.; Cacciola I.; Elia G.; Federico A.; Massironi S.; Guarisco R.; Galioto A.; Ballardini G.; Rendina M.; Nardelli S.; Piano S.; Elia C.; Prestianni L.; Cappa F.M.; Cesarini L.; Simone L.; Pasquale C.; Cavallin M.; Andrealli A.; Fidone F.; Ruggeri M.; Roncadori A.; Baldassarre M.; Tufoni M.; Zaccherini G.; Bernardi M.; Domenicali M.; Giannone F.A.; Merli M.; Gioia S.; Fasolato S.; Sticca A.; Campion D.; Risso A.; Saracco G.M.; Maiorca D.; Rizzotto A.; Lanzi A.; Neri E.; Visani A.; Mastroianni A.; Alberti A.B.; Mazzarelli C.; Vangeli M.; Marzioni M.; Capretti F.; Kostandini A.; Magini G.; Colpani M.; Laffi G.; Gabbani T.; Marsico M.; Zappimbulso M.; Petruzzi J.; Calvaruso V.; Parrella G.; Caporaso N.; Auriemma F.; Guarino M.; Pugliese F.; Gasbarrini A.; Leo P.; De Leonardis F.; Pecchioli A.; Rossi P.; Raimondo G.; Negri E.; Dallio M.; Loguercio C.; Conte D.; Celli N.; Bringiotti R.; Castellaneta N.M.; Salerno F.
08/04/2026 12:58:26
Authors: 305 GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND; 2-s2.0-85038222866 29133514
Journal: Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy
Published: 12531
eng
Volume: Dieci M.V.; Guarneri V.; Giarratano T.; Mion M.; Tortora G.; De Rossi C.; Gori S.; Oliani C.; Merlini L.; Pasini F.; Bonciarelli G.; Griguolo G.; Orvieto E.; Michieletto S.; Saibene T.; Del Bianco P.; De Salvo G.L.; Conte P. Pages: Dieci||Guarneri||Giarratano||Mion||Tortora||De Rossi||Gori||Oliani||Merlini||Pasini||Bonciarelli||Griguolo||Orvieto||Michieletto||Saibene||Del Bianco||De Salvo||Conte-Background: The Breast DX Italy prospective study evaluated the impact of the 21-gene recurrence score (RS) result on adjuvant treatment decisions for patients with early breast cancer. Materials and Methods: Nine centers (two Hub and seven Spoke centers of the Veneto Oncology Network) participated. Consecutive patients with estrogen receptor positive, human epidermal growth receptor negative, T1–T3, N0–N1 early breast cancer were prospectively registered; only those meeting protocol-defined clinicopathological “intermediate risk” criteria were eligible for the RS test. Pre-RS and post-RS physicians’ treatment recommendations and treatment actually received were collected. Results: A total of n = 124 N0 and n = 126 N1 patients underwent the RS assay. The majority had Grade 2 tumors (71%); median age was 55 years, median tumor size was 16 mm, and median Ki67 expression was 20%. Patients enrolled at Hub centers presented higher-risk features. The distribution of RS results was 30 (6.8%). The indication before RS was hormonal therapy (HT) alone in 52% of cases. An indication before RS of chemotherapy (CT)+HT was more frequent for patients with N1 versus N0 tumors (57% vs. 39%, p =.0035) and for patients enrolled at Hub versus Spoke centers (54% vs. 36%, p =.007). The overall rate of change in treatment decision was 16% (n = 40), mostly from CT+HT to HT (n = 30). According to nodal status, rate of change in treatment decision was 12% for the N0 cohort and 20% for the N1 cohort. The proportion of patients recommended to CT+HT was significantly reduced from before to after RS (48% to 40%, p <.0016), especially in the N1 cohort (57% to 45%, p =.0027) and at Hub centers (54% to 44%, p =.001). Conclusion: Despite frequent indication of HT before RS, the use of the RS assay further contributed to sparing CT, especially for patients with N1 tumors and at Hub centers. Implications for Practice: This study shows that, although a high proportion of patients were recommended to receive endocrine treatment alone before knowing the recurrence score (RS) assay, the RS test further contributed in sparing chemotherapy for some of these patients, especially in case of the N1 stage or for patients enrolled at referral centers. These data highlight the need for further work in collaboration with health authorities and companies in order to define strategies for the implementation of the use of RS testing in clinical practice in the Italian setting.
18/04/2026 07:31:14
Authors: 17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A, FRANCE; 2-s2.0-85075825282
Journal: Spain||Italy||Italy||Italy||Italy||Italy||United States||Spain||Italy||Italy||United Kingdom||Australia||Spain||Italy||Chile||Netherlands||Italy||United Kingdom||Italy||Chile||United Kingdom||United Kingdom||Italy||Italy||Italy||Spain||Italy||Italy||Netherlands||Spain||Italy||Italy
Published: 26750
eng
Volume: Costantin L.; Iovino A.; Zibetti S.; Longhetti M.; Gallazzi A.; Mercurio A.; Lonoce I.; Balcells M.; Bolzonella M.; Busarello G.; Dalton G.; Ferre-Mateu A.; Garcia-Benito R.; Gargiulo A.; Haines C.; Jin S.; La Barbera F.; Mcgee S.; Merluzzi P.; Morelli L.; Murphy D.N.A.; Peralta de Arriba L.; Pizzella A.; Poggianti B.M.; Pozzetti L.; Sanchez-Blazquez P.; Talia M.; Tortora C.; Trager S.C.; Vazdekis A.; Vergani D.; Vulcani B. Pages: Costantin||Iovino||Zibetti||Longhetti||Gallazzi||Mercurio||Lonoce||Balcells||Bolzonella||Busarello||Dalton||Ferré-Mateu||García-Benito||Gargiulo||Haines||Jin||La Barbera||Mcgee||Merluzzi||Morelli||Murphy||Peralta de Arriba||Pizzella||Poggianti||Pozzetti||Sánchez-Blázquez||Talia||Tortora||Trager||Vazdekis||Vergani||Vulcani-Context. The upcoming new generation of optical spectrographs on four-meter-class telescopes, with their huge multiplexing capabilities, excellent spectral resolution, and unprecedented wavelength coverage, will provide invaluable information for reconstructing the history of star formation in individual galaxies up to redshifts of about 0.7. Aims. We aim at defining simple but robust and meaningful physical parameters that can be used to trace the coexistence of widely diverse stellar components: younger stellar populations superimposed on the bulk of older ones. Methods. We produced spectra of galaxies closely mimicking data from the forthcoming Stellar Populations at intermediate redshifts Survey (StePS), a survey that uses the WEAVE spectrograph on the William Herschel Telescope. First, we assessed our ability to reliably measure both ultraviolet and optical spectral indices in galaxies of different spectral types for typically expected signal-to-noise ratios. We then analyzed such mock spectra with a Bayesian approach, deriving the probability density function of r- and u-band light-weighted ages as well as of their difference. Results. We find that the ultraviolet indices significantly narrow the uncertainties in estimating the r- and u-band light-weighted ages and their difference in individual galaxies. These diagnostics, robustly retrievable for large galaxy samples even when observed at moderate signal-to-noise ratios, allow us to identify secondary episodes of star formation up to an age of ∼0.1 Gyr for stellar populations older than ∼1.5 Gyr, pushing up to an age of ∼1 Gyr for stellar populations older than ∼5 Gyr. Conclusions. The difference between r-band and u-band light-weighted ages is shown to be a powerful diagnostic to characterize and constrain extended star-formation histories and the presence of young stellar populations on top of older ones. This parameter can be used to explore the interplay between different galaxy star-formation histories and physical parameters such as galaxy mass, size, morphology, and environment.
10/06/2026 07:06:27
Authors: 1661 STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA; 2-s2.0-85066997382 31085341
Journal: Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy
Published: cc-by-nc-nd
eng
Volume: Simbolo M.; Barbi S.; Fassan M.; Mafficini A.; Ali G.; Vicentini C.; Sperandio N.; Corbo V.; Rusev B.; Mastracci L.; Grillo F.; Pilotto S.; Pelosi G.; Pelliccioni S.; Lawlor R.T.; Tortora G.; Fontanini G.; Volante M.; Scarpa A.; Bria E. Pages: Simbolo||Barbi||Fassan||Mafficini||Ali||Vicentini||Sperandio||Corbo||Rusev||Mastracci||Grillo||Pilotto||Pelosi||Pelliccioni||Lawlor||Tortora||Fontanini||Volante||Scarpa||Bria-Introduction: DNA mutational profiling showed that atypical carcinoids (ACs) share alterations with large cell neuroendocrine carcinomas (LCNECs). Transcriptomic studies suggested that LCNECs are composed of two subtypes, one of which shares molecular anomalies with SCLC. The missing piece of information is the transcriptomic relationship between ACs and LCNECs, as a direct comparison is lacking in the literature. Methods: Transcriptomic and genomic alterations were investigated by next-generation sequencing in a discovery set of 14 ACs and 14 LCNECs and validated on 21 ACs and 18 LCNECs by using custom gene panels and immunohistochemistry for Men1 and Rb1. Results: A 58-gene signature distinguished three transcriptional clusters. Cluster 1 comprised 20 LCNECs and one AC harboring concurrent inactivation of tumor protein p53 gene (TP53) and retinoblastoma 1 gene (RB1) in the absence of menin 1 gene (MEN1) mutations; all cases lacked Rb1 nuclear immunostaining. Cluster 3 included 20 ACs and four LCNECs lacking RB1 alterations and having frequent MEN1 (37.5%) and TP53 mutations (16.7%); menin nuclear immunostaining was lost in 75% of cases. Cluster 2 included 14 ACs and eight LCNECs showing intermediate features: TP53, 40.9%; MEN1, 22.7%; and RB1, 18.2%. Patients in cluster C1 had a shorter cancer-specific survival than did patients in C2 or C3. Conclusions: ACs and LCNECs comprise three different and clinically relevant molecular diseases, one AC-enriched group in which MEN1 inactivation plays a major role, one LCNEC-enriched group whose hallmark is RB1 inactivation, and one mixed group with intermediate molecular features. These data support a progression of malignancy that may be traced by using combined molecular and immunohistochemical analysis.
22/05/2026 05:19:07
Authors: 126 ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND; 2-s2.0-85067240300 31319970
Journal: Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy
Published: 12391
eng
Volume: Santo A.; Pilotto S.; Galetta D.; Grossi F.; Fasola G.; Romano G.; Bonanno L.; Bearz A.; Papi M.; Roca E.; Catino A.; Follador A.; Rijavec E.; Genova C.; Petrillo P.; Favaretto A.; Giannone L.; Milella M.; Tortora G.; Giannarelli D.; Bria E. Pages: Santo||Pilotto||Galetta||Grossi||Fasola||Romano||Bonanno||Bearz||Papi||Roca||Catino||Follador||Rijavec||Genova||Petrillo||Favaretto||Giannone||Milella||Tortora||Giannarelli||Bria-Objectives: Considering the frequent expression of somatostatine receptors, we designed the G04.2011 trial to investigate the efficacy of the somatostatine analogue lanreotide in maintenance for SCLC patients after response to standard treatment. Materials and Methods: A multicenter, randomized, phase 3 trial was conducted in SCLC expressing somatostatine receptors at baseline Octreoscan, responding after platinum-based chemotherapy with/without radiotherapy. Patients were randomized 1:1 to receive maintenance lanreotide 120 mg subcutaneously every 28 days, up to 1 year or progression versus observation. Randomization was stratified according to stage (limited/extended, LD/ED). The primary end-point was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and safety. Results: Seventy-one patients were randomly assigned (39 to lanreotide, 32 to observation) in 9 Italian institutions. Median PFS was 3.6 (95% CI 3.2–3.9) with lanreotide versus 2.3 months (95% CI 1.7–2.9) with observation (HR 1.51, 95% CI 0.90–2.50; P = 0.11). Stage was an independent predictor for PFS (HR 3.14, 95% CI 1.77–5.57; P < 0.0001). Median PFS was 7.0 (95% CI <1-13.5) with lanreotide versus 3.8 months (95% CI <1-8.6) with observation in LD (P = 0.21), and 3.0 (95% CI 2.2–3.8) versus 2.2 (95% 1.7–2.7) in ED (P = 0.19). Median OS was 9.5 (95% CI 4.8–14.3) with lanreotide versus 4.7 months (95% CI <1-16.6) with observation (P = 0.47). Treatment-related adverse events occurred in 28% of patients with lanreotide (grade 3 in two patients). Conclusion: Although survival outcomes were not significantly prolonged with lanreotide as a maintenance in SCLC expressing somatostatin receptors after response to standard treatment, lanreotide showed a slight PFS benefit in LD SCLC deserving further investigations.
18/02/2026 06:24:53
Authors: ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND; 2-s2.0-85073710251
Journal: Platelets and hepatocellular cancer: Bridging the bench to the clinics
Published: cc-by
DOI: 10
eng
Volume: Lai Q.; Vitale A.; Manzia T.M.; Foschi F.G.; Sandri G.B.L.; Gambato M.; Melandro F.; Russo F.P.; Miele L.; Vigano L.; Burra P.; Giannini E.G.; Aliberti C.; Baccarani U.; Bhoori S.; Borzio M.; Brancaccio G.; Cabibbo G.; Casadei Gardini A.; Carrai P.; Cillo U.; Conti F.; Cucchetti A.; D'ambrosio R.; Dell'unto C.; Dematthaeis N.; Di Costanzo G.G.; Di Sandro S.; Fucilli F.; Galati G.; Gasbarrini A.; Giuliante F.; Ghinolfi D.; Grieco A.; Gruttaduria S.; Guarino M.; Kostandini A.; Iavarone M.; Lenci I.; Losito F.; Lupo L.G.; Mazzocato S.; Mescoli C.; Miele L.; Morisco F.; Muley M.; Nicolini D.; Persico M.; Pompili M.; Ponziani F.R.; Pravisani R.; Rapaccini G.L.; Rendina M.; Renzulli M.; Rossi M.; Rreka E.; Sacco R.; Sangiovanni A.; Sessa A.; Simonetti N.; Sposito C.; Tortora R.; Trevisani F.; Vigano M.; Villa E.; Vincenzi V.; Violi P.
24/02/2026 12:57:52
Authors: ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND; 2-s2.0-85061982698
Journal: Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy
Published: cc-by
eng
Volume: Dalbeni A.; Ciccarese C.; Bevilacqua M.; Benati M.; Caimmi C.; Cerrito L.; Fama F.; Iacovelli R.; Mantovani A.; Meneguzzi F.M.A.; Minuz P.; Montagnana M.; Orsolini G.; Rossini M.; Tortora G.; Viapiana O.; Fava C. Pages: Dalbeni||Ciccarese||Bevilacqua||Benati||Caimmi||Cerrito||Famà||Iacovelli||Mantovani||Meneguzzi||Minuz||Montagnana||Orsolini||Rossini||Tortora||Viapiana||Fava-Adverse cardiovascular effects, including hypertension, were described in patients with different cancers treated with tyrosine kinase inhibitors (TKI). The mechanism of TKI-related hypertension is still debated. The aim of this work was to study the effects of TKI on blood pressure (BP), searching for a relationship with possible causative factors in patients with metastatic renal cell carcinoma. We included 29 patients in a prospective, observational study; 22 were treated with a first-line drug (sunitinib), while seven participated in the second-line treatment (axitinib or cabozantinib). Patients were investigated at the beginning of antiangiogenic therapy (T0) and at one (T1), three (T2), and six months (T3) after treatment. Patients were evaluated by office blood pressure (BP) and ultrasonography to measure flow-mediated dilatation (FMD), and carotid artery distensibility (cDC) by echocardiography and nailfold capillaroscopy. Plasma endothelin-1 (p-ET-1), urine nitrates, and proteins were also measured. At T1, systolic BP, along with U proteins and p-ET-1, increased significantly. In patients with a clinically significant increase in BP (defined as either the need for an antihypertensive drug or systolic blood pressure (SBP) T1-T0 ≥10 and/or SBP ≥140 mmHg and/or diastolic blood pressure (DBP) T1-T0 ≥5 and/or DBP ≥90 mmHg), the urine nitrate concentration was lower at T0, whereas there were no differences in the p-ET-1 and U proteins. Seventeen participants showed changes in the capillaroscopic pattern at T1 with no association with BP increases. There were no differences in the FMD, cDC, and echocardiographic parameters. Our findings are consistent with those of previous studies about BP increases by TKI, and suggest a role of nitric oxide in BP maintenance in this population.
24/03/2026 09:06:09
Authors: 16604 1155 16TH ST, NW, WASHINGTON, DC 20036 USA; 2-s2.0-85076243842 31751514
Journal: Italy||Italy||Italy||Italy||Italy||Italy||Italy
Published: 26987
eng
Volume: Secchi V.; Iucci G.; Dettin M.; Zamuner A.; De Rosa S.; Tortora L.; Battocchio C. Pages: Secchi||Iucci||Dettin||Zamuner||De Rosa||Tortora||Battocchio-Molecular self-assembly consists of the spontaneous aggregation of molecules into a well-defined structure guided by noncovalent bonds. The self-assembly strategy is ubiquitous in nature and recently has been proposed as a nature-mimetic strategy in polymer science and biomaterial engineering. In this context, we aim at designing and testing innovative but simple chemical strategies to efficiently modify surfaces by exploiting minor modifications in the bioactive molecule functionalities, for example, introducing cysteine (Cys) as a terminal residue in self-assembling peptides (SAPs). In this work, we report the attenuated total reflection-Fourier transform infrared spectroscopy, synchrotron radiation-induced X-ray photoelectron spectroscopy, near-edge X-ray absorption fine structure spectroscopy, and time-of-flight secondary ion mass spectrometry investigation of self-assembled layers of oligopeptides anchored onto gold surfaces through cysteine residues, opportunely inserted in an SAP (EAK16-II) main chain in three different positions: At the amine end group, at the carboxyl end group, and at both terminal groups (i.e., a bidentate SAP). This study, which allowed us to individuate in the bidentate SAP the best candidate for the controlled production of ordered SAP layers on the gold substrate surface, is envisaged to open wide perspectives for efficient chemical modification of surfaces with biomolecules, leading to obtaining innovative bioactive materials for applications in the field of tissue engineering.
18/04/2026 07:15:35
Authors: MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND; 2-s2.0-85074711842
Journal: Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy
Published: cc-by
eng
Volume: Salvatore L.; Calegari M.A.; Loupakis F.; Fassan M.; Di Stefano B.; Bensi M.; Bria E.; Tortora G. Pages: Salvatore||Calegari||Loupakis||Fassan||Di Stefano||Bensi||Bria||Tortora-Molecular assessment of colorectal cancer (CRC) is receiving growing attention, beyond RAS and BRAF, because of its influence on prognosis and prediction in cancer treatment. PTEN (phosphatase and tensin homologue), a tumor suppressor, regulating cell division and apoptosis, has been explored, and significant evidence suggests a role in cetuximab and panitumumab resistance linked to the epidermal growth factor receptor (EGFR) signal transduction pathway. Factors influencing PTEN activity should be analyzed to develop strategies to maximize the tumor suppressor role and to improve tumor response to cancer treatment. Therefore, an in-depth knowledge of the PI3K-Akt pathway—one of the major cancer survival pathways—and the role of PTEN—a major brake of this pathway—is essential in the era of precision medicine. The purpose of this literature review is to summarize the role of PTEN as a predictive factor and possible therapeutic target in CRC, focusing on ongoing studies and the possible implications in clinical practice.
04/06/2026 06:15:03
Authors: ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND; 2-s2.0-85086435592
Journal: Italy||Italy||Italy||Italy||Italy||Russian Federation||Italy||Italy||Italy||Italy
Published: cc-by
eng
Volume: Secchi V.; Franchi S.; Dettin M.; Zamuner A.; Beranova K.; Vladescu A.; Battocchio C.; Graziani V.; Tortora L.; Iucci G. Pages: Secchi||Franchi||Dettin||Zamuner||Beranová||Vladescu||Battocchio||Graziani||Tortora||Iucci-Hydroxyapatite (HAP) coatings can improve the biocompatibility and bioactivity of titanium alloys, such as Ti6Al4V, commonly used as material for orthopedic prostheses. In this framework, we have studied the surface of HAP coatings enriched with Mg and either Si or Ti deposited by RF magnetron sputtering on Ti6Al4V. HAP coatings have been furtherly functionalized by adsorption of a self-assembling peptide (SAP) on the HAP surface, with the aim of increasing the material bioactivity. The selected SAP (peptide sequence AbuEAbuEAbuKAbuKAbuEAbuEAbuKAbuK) is a self-complementary oligopeptide able to generate extended ordered structures by self-assembling in watery solutions. Samples were prepared by incubation of the HAP coatings in SAP solutions and subsequently analyzed by X-Ray Photoelectron Spectroscopy (XPS), Fourier Transform Infrared (FTIR) and Near Edge X-Ray Absorption Fine Structure (NEXAFS) spectroscopies, in order to determine the amount of adsorbed peptide, the peptide stability and the structure of the peptide overlayer on the HAP coatings as a function of the HAP substrate and of the pH of the mother SAP solution. Experimental data yielded evidence of SAP adsorption on the HAP surface, and peptide overlayers showed ordered structure and molecular orientation. The thickness of the SAP overlayer depends on the composition of the HAP coating.